Some companies raise capital. Others raise conviction. BlossomHill Therapeutics just closed an $84M Series B extension, and it landed exactly when it should. Total capital now sits at $257M, but the number that matters more is timing. This round hit as clinical data starts speaking clearly and programs move from theory to proof. That does not happen by accident. That happens when builders know the terrain and respect the climb.
BlossomHill Therapeutics was founded in July 2020 by Jingrong J. Jean Cui and Yishan Y. Peter Li, the same pairing behind Turning Point Therapeutics, later acquired by Bristol Myers Squibb for $4.1B. That history is not trivia. It is muscle memory. They have lived the long nights, the regulatory friction, the chemistry arguments, and the moment when data either shows up or does not. BlossomHill exists because cancer resistance is stubborn and patients do not benefit from recycled science.
The $84M extension was led by Janus Henderson Investors, Brahma Capital, and BioTrack Capital, with continued participation from Cormorant Asset Management, OrbiMed, Vivo Capital, and Plaisance Capital Management. Capital like this does not chase hype. It follows coherence. These investors are backing a macrocyclic small molecule platform designed from scratch, not inherited from prior generations and forced to behave.
BH-30643 is the flagship, a first-in-class OMNI-EGFR inhibitor engineered to handle what usually shuts doors. Complex compound mutations, exon 20 insertions, CNS disease. Early clinical signals from the Phase 1/Phase 2 SOLARA trial showed anti-tumor activity across heavily pretreated EGFR-mutant NSCLC, including brain metastases. This is not chasing EGFR. It is cornering it, selectively, and with intent.
BH-30236 tackles a different battlefield, targeting CLK driven aberrant RNA splicing in relapsed or refractory AML and higher-risk MDS. Phase 1/1b is underway because resistance does not live in one zip code. Cancer adapts fast. BlossomHill designs faster.
The leadership bench matches the ambition. Jingrong J. Jean Cui brings three FDA approved oncology drugs and nearly 30 yrs of design credibility. Yishan Y. Peter Li brings capital discipline and pattern recognition earned the hard way. Geoff Oxnard adds global thoracic cancer gravity. Ashley Preston brings regulatory precision. Vincent Liptak fortifies IP and governance. Eugene Y. Rui anchors chemistry depth. Jason Keyes keeps the financial narrative clean when momentum gets loud.
BlossomHill is named after a hard path that still leads forward. This raise is not celebration fuel. It is execution fuel. In oncology, progress comes molecule by molecule, patient by patient, with zero tolerance for shortcuts.
Startups Startup Funding Venture Capital Series B Biotech Biopharmaceutical Healthcare Health Tech Data Data Driven Technology Innovation Tech Ecosystem Startup Ecosystem
